Onconova Announces Publication Of Positive Phase I Results For Lead Anticancer Compound In Journal Of Clinical Oncology
Onconova Therapeutics, Inc. announced today the publication of positive results from a first-in-human Phase I clinical trial of its lead anticancer drug, ON 01910.Na, in advanced refractory solid tumors. The publication will be online today in the Journal of Clinical Oncology and will appear in a future print edition of the journal. A first-in-class targeted therapy, ON 01910.
More: continued here
Filed under: Cancer on October 29th, 2008